BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar Sells 75,000 Shares

by · The Markets Daily

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) CEO Neil Kumar sold 75,000 shares of BridgeBio Pharma stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $33.40, for a total value of $2,505,000.00. Following the sale, the chief executive officer now directly owns 4,798,447 shares of the company’s stock, valued at approximately $160,268,129.80. The trade was a 1.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Neil Kumar also recently made the following trade(s):

  • On Monday, May 19th, Neil Kumar sold 26,156 shares of BridgeBio Pharma stock. The shares were sold at an average price of $33.33, for a total value of $871,779.48.
  • On Tuesday, April 22nd, Neil Kumar sold 75,000 shares of BridgeBio Pharma stock. The shares were sold at an average price of $34.11, for a total value of $2,558,250.00.
  • On Tuesday, March 25th, Neil Kumar sold 75,000 shares of BridgeBio Pharma stock. The shares were sold at an average price of $36.87, for a total value of $2,765,250.00.
  • On Tuesday, February 25th, Neil Kumar sold 75,000 shares of BridgeBio Pharma stock. The shares were sold at an average price of $33.57, for a total value of $2,517,750.00.
  • On Wednesday, February 19th, Neil Kumar sold 31,543 shares of BridgeBio Pharma stock. The shares were sold at an average price of $36.14, for a total value of $1,139,964.02.

BridgeBio Pharma Stock Performance

NASDAQ BBIO opened at $32.84 on Thursday. BridgeBio Pharma, Inc. has a twelve month low of $21.62 and a twelve month high of $39.54. The stock has a market capitalization of $6.24 billion, a PE ratio of -11.52 and a beta of 1.15. The stock has a 50-day simple moving average of $34.48 and a 200 day simple moving average of $31.73.

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The company reported ($0.88) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.12. The business had revenue of $36.74 million for the quarter, compared to analyst estimates of $57.14 million. During the same period in the prior year, the firm posted ($0.20) EPS. BridgeBio Pharma’s revenue for the quarter was down 44.8% on a year-over-year basis. As a group, equities research analysts forecast that BridgeBio Pharma, Inc. will post -3.67 EPS for the current fiscal year.

Hedge Funds Weigh In On BridgeBio Pharma

Large investors have recently made changes to their positions in the business. GAMMA Investing LLC lifted its position in shares of BridgeBio Pharma by 71.0% during the 1st quarter. GAMMA Investing LLC now owns 920 shares of the company’s stock worth $32,000 after purchasing an additional 382 shares during the last quarter. Jones Financial Companies Lllp acquired a new position in shares of BridgeBio Pharma during the 1st quarter worth about $35,000. Steward Partners Investment Advisory LLC increased its stake in BridgeBio Pharma by 85.8% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company’s stock valued at $28,000 after acquiring an additional 472 shares during the period. Itau Unibanco Holding S.A. bought a new position in BridgeBio Pharma during the fourth quarter valued at about $41,000. Finally, Sterling Capital Management LLC increased its stake in BridgeBio Pharma by 554.6% during the fourth quarter. Sterling Capital Management LLC now owns 1,787 shares of the company’s stock valued at $49,000 after acquiring an additional 1,514 shares during the period. Institutional investors and hedge funds own 99.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Scotiabank lifted their price objective on BridgeBio Pharma from $52.00 to $55.00 and gave the company a “sector outperform” rating in a research report on Wednesday, April 30th. Citigroup increased their price objective on BridgeBio Pharma from $45.00 to $49.00 and gave the company a “buy” rating in a report on Friday, February 21st. JPMorgan Chase & Co. raised their price objective on BridgeBio Pharma from $44.00 to $50.00 and gave the company an “overweight” rating in a research note on Monday, March 24th. UBS Group upped their target price on BridgeBio Pharma from $65.00 to $72.00 and gave the stock a “buy” rating in a research report on Wednesday, April 30th. Finally, HC Wainwright lifted their price target on shares of BridgeBio Pharma from $49.00 to $53.00 and gave the company a “buy” rating in a research report on Tuesday, April 15th. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $57.09.

Check Out Our Latest Analysis on BBIO

About BridgeBio Pharma

(Get Free Report)

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.

See Also